JP2010523696A - 脳腫瘍を治療する方法 - Google Patents
脳腫瘍を治療する方法 Download PDFInfo
- Publication number
- JP2010523696A JP2010523696A JP2010503205A JP2010503205A JP2010523696A JP 2010523696 A JP2010523696 A JP 2010523696A JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010523696 A JP2010523696 A JP 2010523696A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- methoxy
- phenyl
- quinazolin
- amine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title claims abstract description 30
- VYUWDIKZJLOZJL-UHFFFAOYSA-N n-(4-methoxyphenyl)-n,2-dimethylquinazolin-4-amine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1N(C)C1=NC(C)=NC2=CC=CC=C12 VYUWDIKZJLOZJL-UHFFFAOYSA-N 0.000 claims abstract description 82
- 229960004562 carboplatin Drugs 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 19
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 18
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 17
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 21
- 208000005017 glioblastoma Diseases 0.000 claims description 21
- 206010003571 Astrocytoma Diseases 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 10
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 10
- 206010027191 meningioma Diseases 0.000 claims description 10
- 208000002409 gliosarcoma Diseases 0.000 claims description 9
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 9
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims description 9
- 230000000306 recurrent effect Effects 0.000 claims description 9
- 229960004964 temozolomide Drugs 0.000 claims description 8
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 7
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 7
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 7
- 102100021906 Cyclin-O Human genes 0.000 claims description 7
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 7
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 claims description 7
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 7
- 210000003169 central nervous system Anatomy 0.000 claims description 7
- 229960003901 dacarbazine Drugs 0.000 claims description 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 7
- 229960004768 irinotecan Drugs 0.000 claims description 7
- 230000003902 lesion Effects 0.000 claims description 7
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 7
- 229960001278 teniposide Drugs 0.000 claims description 7
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 7
- 229960002066 vinorelbine Drugs 0.000 claims description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 229960000684 cytarabine Drugs 0.000 claims description 6
- 201000007455 central nervous system cancer Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 abstract description 7
- 231100000599 cytotoxic agent Toxicity 0.000 abstract description 6
- 229940045985 antineoplastic platinum compound Drugs 0.000 abstract description 4
- 229940120655 eloxatin Drugs 0.000 abstract description 4
- 150000003058 platinum compounds Chemical class 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 abstract 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 230000004222 uncontrolled growth Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 16
- 238000001802 infusion Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 8
- -1 (4-methoxy-phenyl) -methyl- (2-methyl-quinazoline) Chemical compound 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 208000032612 Glial tumor Diseases 0.000 description 6
- 206010018338 Glioma Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 6
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 6
- 229960000908 idarubicin Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 5
- 208000014644 Brain disease Diseases 0.000 description 5
- 201000010133 Oligodendroglioma Diseases 0.000 description 5
- 208000015114 central nervous system disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010014967 Ependymoma Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 206010059282 Metastases to central nervous system Diseases 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 2
- HAAZMOAXEMIBAJ-UHFFFAOYSA-N 4-chloro-2-methylquinazoline Chemical compound C1=CC=CC2=NC(C)=NC(Cl)=C21 HAAZMOAXEMIBAJ-UHFFFAOYSA-N 0.000 description 2
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940088954 camptosar Drugs 0.000 description 2
- 230000003352 fibrogenic effect Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940061353 temodar Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 201000002844 Cerebellar liponeurocytoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000004378 Choroid plexus papilloma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000021994 Diffuse astrocytoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
- 208000008846 Neurocytoma Diseases 0.000 description 1
- HHAIXNHKPAADOF-UHFFFAOYSA-N ONC(CO)(CO)CO.[Na] Chemical compound ONC(CO)(CO)CO.[Na] HHAIXNHKPAADOF-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037064 Papilloma of choroid plexus Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229940122429 Tubulin inhibitor Drugs 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000014534 anaplastic ependymoma Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 201000010702 central neurocytoma Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000022080 low-grade astrocytoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 201000000393 papillary ependymoma Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000012749 thinning agent Substances 0.000 description 1
- 210000000211 third ventricle Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91097507P | 2007-04-10 | 2007-04-10 | |
| PCT/US2008/059905 WO2008124822A1 (en) | 2007-04-10 | 2008-04-10 | Method of treating brain cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523696A true JP2010523696A (ja) | 2010-07-15 |
| JP2010523696A5 JP2010523696A5 (enExample) | 2011-07-14 |
Family
ID=39831435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503205A Pending JP2010523696A (ja) | 2007-04-10 | 2008-04-10 | 脳腫瘍を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100129470A1 (enExample) |
| EP (1) | EP2144504A4 (enExample) |
| JP (1) | JP2010523696A (enExample) |
| KR (1) | KR20100016385A (enExample) |
| CN (1) | CN101742910A (enExample) |
| AU (1) | AU2008236993A1 (enExample) |
| CA (1) | CA2720982A1 (enExample) |
| NZ (1) | NZ580866A (enExample) |
| WO (1) | WO2008124822A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024095789A (ja) * | 2018-07-31 | 2024-07-10 | 第一三共株式会社 | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772358A (zh) * | 2005-06-16 | 2012-11-14 | 美瑞德生物工程公司 | 药物组合物及其用途 |
| NZ580867A (en) * | 2007-04-10 | 2011-02-25 | Myriad Pharmaceuticals Inc | Method of treating melanoma |
| EP2144887A4 (en) * | 2007-04-10 | 2012-10-03 | Myrexis Inc | PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER |
| WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
| CA2720989A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Methods for treating cancer |
| WO2010006115A1 (en) * | 2008-07-11 | 2010-01-14 | Myriad Pharmaceuticals, Inc. | Pharmaceutical compounds as cytotoxic agents and the use thereof |
| US20110224240A1 (en) * | 2010-01-11 | 2011-09-15 | Myrexis, Inc. | Methods of treating cancer and related diseases |
| KR101343959B1 (ko) | 2012-09-19 | 2013-12-24 | 한국기계연구원 | 통합 코팅 장치 |
| WO2014197569A1 (en) * | 2013-06-05 | 2014-12-11 | Cytrx Corporation | Cytotoxic agents for the treatment of cancer |
| CN105288629B (zh) * | 2014-05-28 | 2021-02-19 | 北京大学 | 具有药效叠加作用及毒性分散效应的组合药物 |
| GB2553716B (en) * | 2015-04-17 | 2020-06-17 | Univ Holy Ghost Duquesne | Pyrrolopyrimidines as antitumor agents |
| IL278311B2 (en) * | 2018-05-02 | 2024-02-01 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Preparations and methods for the treatment of glioblastoma |
| CN111825610B (zh) * | 2020-06-24 | 2023-03-31 | 中国药科大学 | 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524637A (ja) * | 2003-07-03 | 2007-08-30 | ミリアド ジェネティクス， インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン |
| JP2008546713A (ja) * | 2005-06-16 | 2008-12-25 | ミリアド ジェネティクス， インコーポレイテッド | 薬学的組成物およびその使用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0102793A3 (en) * | 1998-05-28 | 2002-07-29 | Parker Hughes Inst St Paul | Quinazolines for treating brain tumor and medicaments containing them |
| US7001926B2 (en) * | 2000-03-10 | 2006-02-21 | Oxigene, Inc. | Tubulin binding agents and corresponding prodrug constructs |
| US20040229960A1 (en) * | 2001-07-13 | 2004-11-18 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| BR0212897A (pt) * | 2001-09-21 | 2004-08-24 | Univ Tulane | Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos |
| US7470723B2 (en) * | 2003-03-05 | 2008-12-30 | Celgene Corporation | Diphenylethylene compounds and uses thereof |
| SG135193A1 (en) * | 2003-08-18 | 2007-09-28 | Pfizer Prod Inc | Dosing schedule for erbb2 anticancer agents |
| GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| AU2006204052A1 (en) * | 2005-01-03 | 2006-07-13 | Cytovia, Inc. | Method of treating brain cancer |
| US8258145B2 (en) * | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US20070249640A1 (en) * | 2005-06-16 | 2007-10-25 | Myriad Genetics, Incorporated | Pharmaceutical compositions and use thereof |
| US20070065449A1 (en) * | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| CA2720989A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Methods for treating cancer |
| EP2144887A4 (en) * | 2007-04-10 | 2012-10-03 | Myrexis Inc | PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER |
| WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
| NZ580867A (en) * | 2007-04-10 | 2011-02-25 | Myriad Pharmaceuticals Inc | Method of treating melanoma |
| WO2009023876A1 (en) * | 2007-08-16 | 2009-02-19 | Myriad Genetics, Inc. | Method of treating non-small cell lung cancer |
-
2008
- 2008-04-10 KR KR1020097023414A patent/KR20100016385A/ko not_active Ceased
- 2008-04-10 WO PCT/US2008/059905 patent/WO2008124822A1/en not_active Ceased
- 2008-04-10 CN CN200880019674A patent/CN101742910A/zh active Pending
- 2008-04-10 CA CA2720982A patent/CA2720982A1/en not_active Abandoned
- 2008-04-10 NZ NZ580866A patent/NZ580866A/en not_active IP Right Cessation
- 2008-04-10 JP JP2010503205A patent/JP2010523696A/ja active Pending
- 2008-04-10 AU AU2008236993A patent/AU2008236993A1/en not_active Abandoned
- 2008-04-10 EP EP08745503A patent/EP2144504A4/en not_active Withdrawn
-
2009
- 2009-10-08 US US12/575,922 patent/US20100129470A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524637A (ja) * | 2003-07-03 | 2007-08-30 | ミリアド ジェネティクス， インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン |
| JP2008546713A (ja) * | 2005-06-16 | 2008-12-25 | ミリアド ジェネティクス， インコーポレイテッド | 薬学的組成物およびその使用 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024095789A (ja) * | 2018-07-31 | 2024-07-10 | 第一三共株式会社 | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 |
| JP7769032B2 (ja) | 2018-07-31 | 2025-11-12 | 第一三共株式会社 | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 |
| JP2026021441A (ja) * | 2018-07-31 | 2026-02-10 | 第一三共株式会社 | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 |
| JP2026021442A (ja) * | 2018-07-31 | 2026-02-10 | 第一三共株式会社 | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100129470A1 (en) | 2010-05-27 |
| WO2008124822A1 (en) | 2008-10-16 |
| EP2144504A1 (en) | 2010-01-20 |
| NZ580866A (en) | 2011-02-25 |
| CN101742910A (zh) | 2010-06-16 |
| KR20100016385A (ko) | 2010-02-12 |
| EP2144504A4 (en) | 2012-10-03 |
| AU2008236993A1 (en) | 2008-10-16 |
| CA2720982A1 (en) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100129470A1 (en) | Method of treating brain cancer | |
| JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| CN104507479B (zh) | 通过联合治疗的半胱天冬酶‑3酶原激活 | |
| JP2001247459A (ja) | 癌の組み合わせ療法 | |
| JP6462147B2 (ja) | Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用 | |
| KR20170012372A (ko) | 뇌암을 치료하기 위한 화합물 | |
| US20100087457A1 (en) | Dosages and methods for the treatment of cancer | |
| US20100087458A1 (en) | Method of treating melanoma | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| US20100261739A1 (en) | Method of Treating Non-Small Cell Lung Cancer | |
| US20100093773A1 (en) | Methods of treating cancer | |
| CN115038447A (zh) | 用于治疗癌症的组合疗法 | |
| TW202114694A (zh) | 四環化合物及其鹽類、組合物、及彼等之使用方法 | |
| KR102005887B1 (ko) | 뇌종양의 예방 또는 치료용 약학 조성물 | |
| AU2008348717A1 (en) | Novel composition for treating the side effects of anticancer treatments | |
| JP2010526073A (ja) | 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体 | |
| CN113993515A (zh) | 使用藏红花酸治疗实体肿瘤的方法 | |
| US9872882B2 (en) | Aurantiamide dipeptide derivatives for treatment or prevention of angiogenesis-related diseases | |
| EP1465617B1 (en) | Process for affecting neurologic progression | |
| TWI602563B (zh) | 橙黃醯胺雙肽衍生物用於治療或預防血管新生相關疾病 | |
| WO2009104152A1 (en) | Combination treatment for ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110408 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120327 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130326 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130402 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130506 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130514 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131030 |